15262-77-8

Basic information

• Product Name: delmadinone
• Synonyms: delmadinone;6-Chloro-17-hydroxypregna-1,4,6-triene-3,20-dione;Δ1-ChlorMadinone
• CAS NO: 15262-77-8
• Molecular Formula: C21H25ClO3
• Molecular Weight: 360.87
• EINECS: 239-306-6
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
• Mol File: 15262-77-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 515.058 °C at 760 mmHg
• Flash Point: 265.298 °C
• Appearance: /
• Density: 1.271 g/cm³
• Vapor Pressure: 9.19E-13mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 12.86±0.70(Predicted)
• CAS DataBase Reference: delmadinone(CAS DataBase Reference)
• NIST Chemistry Reference: delmadinone(15262-77-8)
• EPA Substance Registry System: delmadinone(15262-77-8)

Safety Data

• Hazardous Substances Data: 15262-77-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C21H25ClO3/c1-12(23)21(25)9-6-16-14-11-18(22)17-10-13(24)4-7-19(17,2)15(14)5-8-20(16,21)3/h4,7,10-11,14-16,25H,5-6,8-9H2,1-3H3

Upstream product

• 66212-25-7 1,4,6-triene-3,20-dione-17α-hydroxyprogesterone 
• 633-35-2 1,4,6-androstatriene-3,17-dione 

Related news

Implant Pellets I: Effects of Compression Pressure on In Vivo Dissolution of delmadinone (cas 15262-77-8) Acetate Pellets08/04/2019

A formulation containing 95% delmadinone acetate was compressed at three different pressures. These pressures resulted in a pellet density difference of 19%. In vivo dissolution profiles were determined for five lots of pellets. The pellets were implanted subcutaneously in rats, removed periodic...detailed

Biotransformation of chlormadinone acetate to delmadinone (cas 15262-77-8) acetate by free and immobilized Arthrobacter simplex ATCC 6946 and Bacillus sphaericus ATCC 1380508/03/2019

Microbial transformation of chlormadinone acetate to delmadinone acetate was investigated using free and immobilized cells of Arthrobacter simplex ATCC 6946 and Bacillus sphaericus ATCC 13805 in liquid–liquid biphasic system and a liposomal medium. For liquid–liquid biphasic system, n-decane, ...detailed

Factors affecting the biotransformation of chlormadinone acetate to delmadinone (cas 15262-77-8) acetate08/02/2019

Factors affecting the aqueous biotransformation of chlormadinone acetate to delmadinone acetate by freely suspended cells of Arthrobacter simplex ATCC 6946 and Bacillus sphaericus ATCC 13805 were investigated. The effects of exogenous electron carrier (menadione), cosolvent (dimethylformamide), ...detailed

Relevant articles and documents

Method for preparing delmadinone acetate product

The invention provides a method for preparing a delmadinone acetate product. The method comprises the following steps: by taking IDD (1,4-Androstadienedione) as a raw material, firstly, enabling 17-site ketone in IDD molecules to react with acetone cyanohydrins in a first organic solvent under catalysis of an alkali, and introducing beta-hydroxyl and alpha-cyan into the 17-site so as to obtain hydroxyl cyanogens; preparing 1,6-bidehydrogenation-17a-hydroxyl progesterone from the hydroxyl cyanogens in the presence of methyl magnesium halide, a second organic solvent and an acid; further synthesizing a 6-site epoxy substance, further synthesizing 6-site chloride so as to obtain delmadinone, and finally carrying out 17-site esterification so as to obtain delmadinone acetate; and further carrying out heating backflow decoloring and recrystalization on the obtained delmadinone acetate with activated carbon in lower-carbon alcohol with the carbon number of smaller than 4, thereby obtaining the delmadinone acetate product. Compared with a conventional synthesis method, the method provided by the invention has multiple advantages of being simple and convenient in process operation, economic and environmental-friendly in production, high in total synthesis yield, high in product quality, low in production cost, and the like.

Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate

A pharmaceutical composition comprising an anti-estrogen and an antigonadotropically effective anti-androgen, e.g., in a weight ratio of anti-estrogen to anti-androgen of essentially 2:1 to 1:10 is effective for the prophylaxis and therapy of prostate hyperplasia. Suitable anti-estrogens include, for example, tamoxifen. Antigonadotropically active anti-androgens preferably are steroids having anti-androgenic and progestational properties, e.g., cyproterone acetate.